If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmmerson Regulatory News (EML)

Share Price Information for Emmerson (EML)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.40
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.20 (8.696%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.40
EML Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Liberum as Nominated Advisor

3 Jan 2023 07:00

RNS Number : 4066L
Emmerson PLC
03 January 2023
 

 

 

 

Emmerson PLC / Ticker: EML / Index: LSE / Sector: Mining

 

3 January 2023

 

Emmerson PLC ("Emmerson" or the "Company")

 

Appointment of Liberum as Nominated Advisor

 

Emmerson PLC, the Moroccan focused potash development company, is pleased to announce the appointment of Liberum Capital as Nominated Advisor to the Company with immediate effect.

Graham Clarke, CEO, commented:

"I am delighted to appoint Liberum Capital as Nominated Advisor, having now worked with the team since they became joint broker to Emmerson in February 2022. Liberum is a well-respected mid-tier stockbroker with a strong mining franchise which will be the right fit to take the Company into its next stage of construction and first production."

**ENDS**

 

For further information, please visit www.emmersonplc.com, follow us on Twitter (@emmerson_plc), or contact: 

 

Emmerson PLC

Graham Clarke / Jim Wynn / Charles Vaughan

 

 

+44 (0) 20 7236 1177

Liberum Capital Limited (Nominated Advisor and Joint Broker)

Scott Mathieson / William King

+44 (0)20 3100 2000

Shard Capital (Joint Broker)

Damon Heath / Isabella Pierre

 

 

+44 (0)20 7186 9927

 

 

St Brides Partners (Financial PR/IR)

Susie Geliher / Charlotte Page

 

+44 (0)20 7236 1177

 

 

 

 

 

Notes to Editors

Emmerson is focused on advancing the Khemisset project ("Khemisset" or the "Project") in Morocco into a low cost, high margin supplier of potash, and the first primary producer on the African continent. With an initial 19-year life of mine, the development of Khemisset is expected to deliver long-term investment and financial contributions to Morocco including the creation of permanent employment, taxation, and a plethora of ancillary benefits. As a UK-Moroccan partnership, the Company is committed to bringing in significant international investment over the life of the mine.

 

Morocco is widely recognised as one of the leading phosphate producers globally, ranking second in the world in terms of tonnes produced annually, and the development of this mine is set to consolidate its position as the most important fertiliser producer in Africa. The Project has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K2O, with significant exploration potential, and is perfectly located to support the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. The need to feed the world's rapidly increasing population is driving demand for potash and Khemisset is well placed to benefit from the opportunities this presents. The Feasibility Study released in June 2020 indicated the Project has the potential to be among the lowest capital cost development stage potash projects in the world and also, as a result of its location, one of the highest margin projects. This delivered outstanding economics, including a post-tax NPV8 of approximately US$1.4 billion using industry expert Argus' price forecasts, and the spot price for granular MOP fertiliser has since risen, further enhancing the valuations.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPVLLFBXFLEBBB
Date   Source Headline
22nd Apr 202411:47 amRNSTR-1: Notification of major holdings
8th Apr 20244:45 pmRNSResults of Oversubscribed REX Retail Offer
8th Apr 20247:01 amRNSREX Retail Offer
8th Apr 20247:00 amRNSQ1 Update, Equity Placing and Retail Offer
11th Mar 20247:00 amRNSCommittee Upholds Environmental Approval Referral
1st Feb 20247:00 amRNSScoping Study on Breakthrough New Processing Route
8th Jan 20247:00 amRNSQ4 Update
21st Dec 20237:00 amRNSExtension of Mandated Lead Arrangers
26th Sep 20237:00 amRNSInterim Results for the six months to 30 June 2023
21st Sep 20237:00 amRNSQ3 2023 and Financing update
11th Sep 202311:38 amRNSMorocco Statement
11th Jul 202311:57 amRNSDirector/PDMR Shareholding
10th Jul 20234:30 pmRNSDirector/PDMR Shareholding
6th Jul 20232:49 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSQ2 Update
6th Jun 20237:00 amRNSExercise & Allotment of Shares
31st May 202312:01 pmRNSResult of AGM
5th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
13th Apr 20237:00 amRNS2022 Financial Results and Q1 Update
14th Feb 20237:00 amRNSMandated Lead Arrangers Appointed for Financing
9th Jan 20237:00 amRNSQ4 Update
3rd Jan 20237:00 amRNSAppointment of Liberum as Nominated Advisor
21st Nov 20227:00 amRNSPotash and Salt Offtake MOUs
27th Sep 20227:00 amRNSDirector/PDMR Shareholding
26th Sep 20221:45 pmRNSResults of REX Retail Offer & Total Voting Rights
26th Sep 20227:02 amRNSREX Retail Offer
26th Sep 20227:01 amRNSRenewal of Strategic Investment & Equity Placing
26th Sep 20227:00 amRNSInterim Results for the six months to 30 June 2022
16th Aug 20224:18 pmRNSExercise of Options & Director/PDMR Shareholding
22nd Jul 20229:00 amRNSShare Options Scheme & Director Shareholdings
19th Jul 20225:05 pmRNSReplacement: Director/PDMR Shareholding
18th Jul 20224:00 pmRNSDirector/PDMR Shareholding
11th Jul 20227:00 amRNSQ2 Activities Update
7th Jul 202212:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSExercise of Warrants and Issue of Shares
13th Jun 20227:00 amRNSNotice of AGM and Posting of Annual Report
31st May 20227:00 amRNSAudited Results for the year ended 31 Dec 2021
31st Mar 20227:00 amRNSQ1 Activities Update
15th Mar 20227:00 amRNSGrant of Share Options
21st Feb 20227:00 amRNSAppointment of Chief Financial Officer
16th Feb 20227:00 amRNSAppointment of Corporate Broker
27th Jan 20227:00 amRNSBasic Engineering Packages Awarded to Reminex S.A
25th Jan 20221:00 pmRNSPart Exercise of Options and Issue of Shares
31st Dec 20217:00 amRNSEnd of Year Newsletter
6th Dec 202112:45 pmRNSResult of AGM
6th Dec 202112:31 pmRNSResult of General Meeting
2nd Dec 20217:00 amRNSOperational Update: Khemisset Potash Project
29th Nov 20217:00 amRNSDirector/PDMR Shareholding
24th Nov 20217:00 amRNSIssue of Equity & Total Voting Rights
12th Nov 20217:00 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.